OMA Guidelines Bundle

Obesity Pharmacotherapy Supplements 2026

Obesity Medicine Association OMA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1544296

Contents of this Issue

Navigation

Page 10 of 19

11 Common AEs Key Interactions/Notes Avg. Wt Loss vs. Placebo Oily stools/flatus (esp. high-fat meals), gallstones, kidney stones, fat-soluble vitamins May reduce absorption of cyclosporine, oral contraceptives (OCs), antiseizure meds, thyroid hormone, warfarin; take multivitamin ≥2 h apart ~2.9% Nausea, constipation/ diarrhea, headache (HA), vomiting, dizziness, insomnia, dry mouth Avoid opioids, MAOIs; interactions with antiseizure meds; potential to lower seizure threshold; rare angle- closure glaucoma; suicidality risk <24 y with bupropion ~5% As phentermine +paresthesia, dizziness, dysgeusia; monitor mood/sleep, cognition; metabolic acidosis, nephrolithiasis Teratogenic, conf irm not pregnant; avoid MAOIs and alcohol; caution with non-K sparing diuretics (hypokalemia) ~9% Nausea, vomiting, bloating, diarrhea/ constipation, dyspepsia, abd pain, fatigue, dizziness, HA; lipase; rare renal issues Can worsen diabetic retinopathy; stop if pancreatitis, gallbladder disease, suicidality; hypoglycemia with insulin/ sulfonylureas (SU); slows gastric emptying (affects oral meds incl. OCs) ~4.5% Similar to liraglutide (primarily GI) Same precautions as liraglutide ~12.4% Similar to liraglutide; fewer GI discontinuations vs semaglutide Same class precautions as GLP-1 RAs ~18.4%

Articles in this issue

Archives of this issue

view archives of OMA Guidelines Bundle - Obesity Pharmacotherapy Supplements 2026